Posted by: fuadelhibri on: April 13, 2011
2010 revenues of $286.2 million 2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability 2010 cash, investments and accounts receivable balance of $210.4 million 2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million Emergent BioSolutions Inc. (NYSE: EBS) announced [...]
Posted by: fuadelhibri on: August 17, 2009
Type: Public On the web: http://www.emergentbiosolutions.com Employees: 587 Employee growth: 4.8% Emergent BioSolutions protects your thorax against anthrax. Emergent BioSolutions develops and produces, for government and commercial markets, drugs that treat or protect against infectious diseases and bio-agents. The company supplies BioThrax (the US’s only FDA-approved anthrax vaccine) primarily to the departments of Defense and [...]
